Procept Biorobotics Insider Sold Shares Worth $1,811,653, According to a Recent SEC Filing
Express News | Procept Biorobotics Corp : Leerink Partners Raises Target Price to $86 From $78
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), PROCEPT BioRobotics (PRCT) and Travere Therapeutics (TVTX)
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $75 to $99
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $99
Piper Sandler Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $75
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics Says FDA Has Approved Pivotal Investigational Device Exemption Clinical Trial Comparing Aquablation Therapy To Radical Prostatectomy
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
Express News | Procept Biorobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
PROCEPT BioRobotics Corporation (PRCT) Advances Urology With AI-Integrated HYDROS Robotic System; Price Target Raised to $99
Jim Cramer Prefers Intuitive Surgical, Inc. (NASDAQ:ISRG) Over Procept Biorobotics
Is Procept Biorobotics Corp. (PRCT) the Worst AI Stock to Buy?
Procept Biorobotics Corporation (PRCT): Why Are Short Sellers Betting Against This Hospital Tech Innovator?
Procept Biorobotics Insider Sold Shares Worth $2,062,679, According to a Recent SEC Filing
Form 144 | PROCEPT BioRobotics(PRCT.US) Insider Proposes to Sell 4.06 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 16, $PROCEPT BioRobotics(PRCT.US)$ Insider Kevin Waters intends to sell 50,000 shares of its common stock on Sep 16, with a total market value of approximately $4.06
PROCEPT BioRobotics Currently Up Nine Consecutive Days, Longest Winning Streak Since September 2023 -- Data Talk